DAC upregulated OCT3 expression in CRC cells with OCT3 low expression, which may be of great significance in reversing anticancer drug resistance to OCT3 substrates (25,26), including OXA in CRC. This evidence concerns the gene SLC22A3 and colorectal carcinoma.